Vials of the experimental antiviral obeldesivir, developed by Gilead Sciences, which is being evaluated in a clinical trial in the Democratic Republic of Congo to determine whether it can prevent Ebola infection after high-risk exposure.
Vials of the experimental antiviral obeldesivir, developed by Gilead Sciences, which is being evaluated in a clinical trial in the Democratic Republic of Congo to determine whether it can prevent Ebola infection after high-risk exposure.